Details for Patent: 10,612,027
✉ Email this page to a colleague
Which drugs does patent 10,612,027 protect, and when does it expire?
Patent 10,612,027 protects OXLUMO and is included in one NDA.
This patent has twenty-five patent family members in eleven countries.
Summary for Patent: 10,612,027
| Title: | Modified double-stranded RNA agents |
| Abstract: | One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2'-OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions. |
| Inventor(s): | Maier; Martin (Cambridge, MA), Foster; Don (Cambridge, MA), Milstein; Stuart (Cambridge, MA), Kuchimanchi; Satya (Cambridge, MA), Jadhav; Vasant (Cambridge, MA), Rajeev; Kallanthottathil (Cambridge, MA), Manoharan; Muthiah (Cambridge, MA), Parmar; Rubina (Cambridge, MA) |
| Assignee: | ALNYLAM PHARMACEUTICALS, INC. (Cambridge, MA) |
| Application Number: | 16/384,644 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Delivery; |
Drugs Protected by US Patent 10,612,027
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,612,027
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2958758 | ⤷ Try a Trial | |||
| China | 107075516 | ⤷ Try a Trial | |||
| China | 114181942 | ⤷ Try a Trial | |||
| Eurasian Patent Organization | 201790420 | ⤷ Try a Trial | |||
| European Patent Office | 3186377 | ⤷ Try a Trial | |||
| European Patent Office | 3808846 | ⤷ Try a Trial | |||
| European Patent Office | 3812462 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
